Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 2, 14, 15, 13, 12, 16, 2, 2, 17, 1, 17, 8, 18, 12, 19, 12, 20, 21, 22, 23, 24, 25, 12, 1on behalf of the TICO Study Group

1CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark

2Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK

3Hennepin Healthcare Research Institute, Minneapolis, MN, USA

4Department of Medicine, School of Medicine, University of Minnesota, Minneapolis, MN, USA

5Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University, Durham, NC, USA

6Intermountain Medical Center, Murray, UT, USA

7University of Utah School of Medicine, Salt Lake City, UT, USA

8The Kirby Institute, University of New South Wales Sydney, Sydney, NSW, Australia

9U.S. Department of Veterans Affairs, Washington, DC, USA

10Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA

11Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA

12Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA

13National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

14Veteran Affairs Medical Center, Washington, DC, USA

15School of Medicine & Health Sciences, The George Washington University, Washington, DC, USA

16Infectious Diseases Department & IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Catalonia, Spain

17Institute for Global Health, University College London, London, UK

18St Vincent’s Hospital Sydney, Darlinghurst, NSW, Australia

19Division of Infectious Diseases, Baylor University Medical Center, Dallas, TX, USA

20Leidos Biomedical Research, Inc., Frederick, MD, USA

21Division of Pulmonary and Critical Care, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

22Harvard Medical School, Boston, MA, USA

23National Centre for Infectious Diseases, Singapore

24Tan Tock Seng Hospital, Singapore

25Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore


Corresponding Author:

Daniel D Murray, CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, 2100 Copenhagen, Denmark. Email:

留言 (0)

沒有登入
gif